Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PCL
MCID: PLS016
MIFTS: 43

Plasma Cell Leukemia (PCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasma Cell Leukemia

About this section

MalaCards integrated aliases for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 53 59 55
Leukemia, Plasma Cell 53 73
Pcl 59

Characteristics:

Orphanet epidemiological data:

59
plasma cell leukemia
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA454714
UMLS via Orphanet 74 C0023484
ICD10 via Orphanet 34 C90.1
ICD10 33 C90.1
UMLS 73 C0023484
Sources

Summaries for Plasma Cell Leukemia

About this section
NIH Rare Diseases : 53 Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers. Different types of treatments are available for patients with PCL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. For detailed information on the available treatment options, please visit the following link. http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient/page4

MalaCards based summary : Plasma Cell Leukemia, also known as leukemia, plasma cell, is related to myeloma, multiple and monoclonal gammopathy of uncertain significance. An important gene associated with Plasma Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Interleukin-4 and 13 signaling. The drugs Bortezomib and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotype is vision/eye.

Wikipedia : 76 Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant... more...

Sources

Related Diseases for Plasma Cell Leukemia

About this section

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 myeloma, multiple 31.2 CCND1 FGFR3 IRF4 MAF NCAM1
2 monoclonal gammopathy of uncertain significance 29.5 FGFR3 MAF NCAM1
3 lymphoma, mucosa-associated lymphoid type 29.5 CCND1 IRF4
4 lymphedema, hereditary, ia 11.3
5 plasmacytic leukemia 11.3
6 hereditary lymphedema i 11.1
7 leukemia 11.0
8 tropical calcific pancreatitis 10.6
9 lymphoma 10.2
10 plasmacytoma 10.1
11 colorectal cancer 10.0
12 hairy nose tip 10.0
13 prostate cancer 10.0
14 personality disorder 10.0
15 primary orthostatic tremor 10.0
16 chondromyxoid fibroma 10.0 CCND1 FGFR3
17 bladder disease 10.0 CCND1 FGFR3
18 marginal zone b-cell lymphoma 10.0 CCND1 IRF4
19 papilloma 10.0 CCND1 FGFR3
20 follicular lymphoma 9.9 CCND1 IRF4
21 angioimmunoblastic t-cell lymphoma 9.9
22 pheochromocytoma 9.9
23 lung cancer 9.9
24 gastric cancer 9.9
25 tendinosis 9.9
26 pemphigus foliaceus 9.9
27 spinal cord injury 9.9
28 adrenal gland pheochromocytoma 9.9
29 antisocial personality disorder 9.9
30 neuroendocrine tumor 9.9
31 post-traumatic stress disorder 9.9
32 glioblastoma multiforme 9.9
33 glioblastoma 9.9
34 trochlear dysplasia 9.9
35 osteoporotic fracture 9.9
36 epithelial predominant wilms' tumor 9.9 MAF NCAM1
37 bladder urothelial carcinoma 9.9 CCND1 FGFR3
38 nephrogenic adenofibroma 9.9 MAF NCAM1
39 bile duct cancer 9.9 CCND1 NCAM1
40 myelofibrosis 9.8
41 leukemia, chronic myeloid 9.8
42 human herpesvirus 8 9.8
43 hematopoietic stem cell transplantation 9.8
44 peripheral t-cell lymphoma 9.8
45 myeloid leukemia 9.8
46 macroglobulinemia 9.8
47 amyloidosis 9.8
48 gastrointestinal stromal tumor 9.8 CCND1 NCAM1
49 b-cell lymphomas 9.8 CCND1 IRF4
50 leukemia, chronic lymphocytic 2 9.7

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia
Sources

Symptoms & Phenotypes for Plasma Cell Leukemia

About this section

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 8.92 CCND1 FGFR3 MAF NCAM1
Sources

Drugs & Therapeutics for Plasma Cell Leukemia

About this section

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
4
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
5
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
6
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
7
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
8
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
9
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
10
Lenograstim Approved, Investigational Phase 1, Phase 2,Phase 2 135968-09-1
11
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
12
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
13
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
14
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
15
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
16
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
17 Pomalidomide Approved Phase 2 19171-19-8
18 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
19
Daratumumab Approved Phase 2,Phase 1 945721-28-8
20
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22 tannic acid Approved Phase 2
23
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
24
Promethazine Approved, Investigational Phase 2 60-87-7 4927
25
Allopurinol Approved Phase 2 315-30-0 2094
26
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
27
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
28
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
29
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
30
Acetaminophen Approved Phase 2 103-90-2 1983
31
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
32
Everolimus Approved Phase 2 159351-69-6 6442177
33
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
34
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
35
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 32326 21704
36
Pegaspargase Approved, Investigational Phase 2 130167-69-0
37
Glycine Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 56-40-6 750
38
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 77-92-9 311
39
Doxil Approved June 1999 Phase 2,Phase 1 31703
40
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 2,Phase 1
44 Antiemetics Phase 2,Phase 1
45 HIV Protease Inhibitors Phase 2,Phase 1
46 Immunoglobulin A Phase 2
47 Gastrointestinal Agents Phase 2,Phase 1
48 glucocorticoids Phase 2,Phase 1
49 Hormone Antagonists Phase 2,Phase 1
50
protease inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Unknown status NCT01435720 Phase 1, Phase 2
3 Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
4 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 Completed NCT02858999 Phase 2 PAD-VCD
5 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Completed NCT00307086 Phase 2 Bortezomib;Melphalan
6 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
7 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
8 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
9 Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma Recruiting NCT01729091 Phase 2 Lenalidomide;Melphalan
10 MUK Nine b: OPTIMUM Treatment Protocol Recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
11 Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Recruiting NCT02506959 Phase 2 Busulfan;Gemcitabine Hydrochloride;Melphalan;Panobinostat
12 Allo HSCT Using RIC for Hematological Diseases Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
13 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Recruiting NCT03314974 Phase 2
14 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
15 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Active, not recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
16 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
17 Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant Not yet recruiting NCT03622788 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
18 Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
19 Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
20 Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Terminated NCT00837200 Phase 2 Oncaspar, Doxil, Decadron
21 Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
22 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies Unknown status NCT00988013 Phase 1
23 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
24 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
25 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Recruiting NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
26 SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting NCT02334865 Phase 1 Lenalidomide
27 Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Active, not recruiting NCT01372540 Phase 1 Carfilzomib;Filanesib
28 MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Suspended NCT03031730 Phase 1 Carfilzomib;Dexamethasone;Lenalidomide;MDM2 Inhibitor AMG-232
29 Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia Withdrawn NCT03591744 Phase 1 Bortezomib;Dexamethasone;Lenalidomide;Pegylated Liposomal Doxorubicin Hydrochloride
30 Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
31 High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT03389347 Not Applicable
32 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Recruiting NCT01962636 Not Applicable Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil
33 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844

Search NIH Clinical Center for Plasma Cell Leukemia

Sources

Genetic Tests for Plasma Cell Leukemia

About this section
Sources

Anatomical Context for Plasma Cell Leukemia

About this section

MalaCards organs/tissues related to Plasma Cell Leukemia:

41
Bone, Bone Marrow, Testes, T Cells, Myeloid, Thyroid, B Cells
Sources

Publications for Plasma Cell Leukemia

About this section

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 410)
# Title Authors Year
1
A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. ( 29892544 )
2018
2
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome. ( 29501828 )
2018
3
Lymphoplasmacytoid cytology in plasma cell leukemia. ( 29027254 )
2018
4
Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy. ( 29582109 )
2018
5
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. ( 29523783 )
2018
6
Primary Nonsecretory Plasma Cell Leukemia With Multiple Chromosomal Abnormalities: A Case Report. ( 29664669 )
2018
7
Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia. ( 29417202 )
2018
8
Plasma Cell Leukemia Masquerading as a Relapse of the Nephrotic Syndrome. ( 29401321 )
2018
9
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. ( 29965787 )
2018
10
Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). ( 29064593 )
2018
11
Plasma cell leukemia presenting as &amp;quot;lymphocytosis&amp;quot;. ( 29699997 )
2018
12
Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate. ( 30488870 )
2018
13
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. ( 30442928 )
2018
14
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. ( 30446740 )
2018
15
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). ( 30370955 )
2018
16
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. ( 30332496 )
2018
17
Global methylation patterns in primary plasma cell leukemia. ( 30257227 )
2018
18
Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry. ( 30013912 )
2018
19
Plasma cell leukemia. ( 30090796 )
2018
20
Rare and unusual case of anti-factor XI antibodies in patient with plasma cell leukemia. ( 30116534 )
2018
21
Meningeal Involvement in Primary Plasma Cell Leukemia. ( 30127574 )
2018
22
Acute Renal failure caused by plasma cell infiltration in primary plasma cell leukemia. ( 28792128 )
2017
23
Leukemia Cutis Associated with Secondary Plasma Cell Leukemia. ( 28620566 )
2017
24
Progression of cutaneous plasmacytoma to plasma cell leukemia in a dog. ( 28186653 )
2017
25
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient. ( 28286633 )
2017
26
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). ( 29108331 )
2017
27
Flaming plasma cell leukemia. ( 28120778 )
2017
28
IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review. ( 29066491 )
2017
29
A case of primary plasma cell leukemia exhibiting hemophagocytic plasma cells relapsed with multiple cutaneous plasmacytoma. ( 29333413 )
2017
30
Plasmacytomas and Plasma-Cell Leukemia. ( 28296609 )
2017
31
Plasma Cell Leukemia Presenting with Hyperleukocytosis and Anaplasia. ( 28194071 )
2017
32
Histone deacetylase inhibitors in plasma cell leukemia treatment: Effect of bone marrow microenvironment. ( 28043150 )
2017
33
Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. ( 28255016 )
2017
34
Plasma cell leukemia: update on biology and therapy. ( 27819179 )
2017
35
Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry. ( 28270351 )
2017
36
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. ( 28544116 )
2017
37
Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma. ( 29430310 )
2017
38
Rapid Fatal Acute Peripheral T-Cell Lymphoma Associated With IgG Plasma Cell Leukemia and IgA Hypergammaglobulinemia. ( 27824644 )
2016
39
Primary plasma cell leukemia 2.0: advances in biology and clinical management. ( 27759436 )
2016
40
Plasma cell leukemia: Single institution experience. ( 28485366 )
2016
41
Primary Plasma Cell Leukemia: Identity Card 2016. ( 26995215 )
2016
42
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. ( 28038447 )
2016
43
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. ( 26505781 )
2016
44
Hemorrhagic Skin Nodules and Plaques: A Diagnostic Clue to Underlying Primary Plasma Cell Leukemia. ( 27057024 )
2016
45
Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature. ( 27721294 )
2016
46
Confusing Hairy Cells in a Case of IgG Kappa Plasma Cell Leukemia. ( 27215099 )
2016
47
Progress in the Treatment of Primary Plasma Cell Leukemia. ( 27114588 )
2016
48
Plasma Cell Leukemia With Prominent Hairy-cell Morphology. ( 27916226 )
2016
49
Radiographic features of plasma cell leukemia in the maxilla: A case report. ( 28035306 )
2016
50
Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. ( 27103978 )
2016
Sources

Variations for Plasma Cell Leukemia

About this section
Sources

Expression for Plasma Cell Leukemia

About this section
Search GEO for disease gene expression data for Plasma Cell Leukemia.
Sources

Pathways for Plasma Cell Leukemia

About this section

Pathways related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 12.03 CCND1 FGFR3 IRF4 NCAM1
2
Interleukin-4 and 13 signaling 66
11.49 CCND1 IRF4
3
Innate Lymphoid Cell Differentiation Pathways 65
11.31 IRF4 NCAM1
4
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.27 FGFR3 NCAM1
5
C-MYB transcription factor network 1
11.21 CCND1 MAF
6
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.14 IRF4 MAF
7
Dendritic Cells Developmental Lineage Pathway 65
11.02 IRF4 NCAM1
8
Bladder cancer 37 1
10.82 CCND1 FGFR3
Sources

GO Terms for Plasma Cell Leukemia

About this section

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 8.62 IRF4 NCAM1

Molecular functions related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.62 FGFR3 NCAM1
Sources

Sources for Plasma Cell Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....